Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.
|Videos|November 22, 2022
PharmExec Interviews at Pharma Lalarukh Haris Shaikh 2022
Advertisement
In this video, “Lala” Haris Shaikh, PhD, Executive Vice President, Life Sciences & Biotech, Palantir Technologies discusses the digital transformation with pharma data, how that can be done, data insights for pharma leaders as well as data interoperability and integration issues.
Advertisement
Related to this article
Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Inizio's Elaine Ferguson on how cross-functional leadership pods tackling real business challenges are turning talent development into operational innovation.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Onswik for Adults with Type 2 Diabetes
2
What Actually Went Wrong When a Phase 3 Trial Fails: Q&A with Dr. Remo Moomiaie-Qajar
3
From Experimentation to Execution: Strategic AI Adoption and Clinical Data Harmonization in Life Sciences
4
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly
5